ClinicalTrials.gg
CompletedNCT00175916Updated Aug 17, 2021Results posted

Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy

A Phase 3 interventional study of Brivaracetam (ucb 34714) in Epilepsy, sponsored by UCB Pharma. Completed at 153 sites in 26 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
853
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
Largest of 34
853 · median 94
Started
2005
with 3 others
Phase 3
21 of 34
1 open now
Registered
2nd of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one has the largest enrollment, is one of 4 that started in 2005, is one of 21 in phase 3, and was the 2nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Epilepsy
  • long term
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female subjects from 16 years (where legally permitted and ethically accepted) or 18 years onwards suffering from epilepsy and having completed a previous study with brivaracetam as adjunctive treatment, which allowed access to this study
  • Subjects with POS/PGS: inpatients or outpatients with epilepsy who participated in previous brivaracetam studies / programs which allow access to the present study
  • Subjects with ULD: inpatients or outpatients with epilepsy who were treated with brivaracetam in previous studies / programs which allow access to the present study
  • Subjects for whom the Investigator believes a reasonable benefit from the long-term administration of brivaracetam may be expected

Exclusion criteria

Exclusion Criteria:

  • Severe medical, neurological and psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
  • Poor compliance with visit schedule or medication intake in previous brivaracetam study
  • Participation in any clinical study of another drug or device during the study
  • Pregnant or lactating woman
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
853 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Flexible dosing, can up and down titrate as needed.

    Drug: Brivaracetam (ucb 34714)

Interventions

  • 10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

    Treatment-emergent adverse events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.

    Time frame: From Entry Visit until Last Visit (up to 162 months)

  2. Percentage of Participants Who Withdrew Due to an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.

    Time frame: From Entry Visit until Last Visit (up to 162 months)

  3. Percentage of Participants With at Least One Serious Adverse Event (SAE)

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is an infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Entry Visit until Last Visit (up to 162 months)

Secondary outcomes

  1. Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

    The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

    Time frame: From Entry Visit until Last Visit (up to 162 months)

  2. Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

    The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

    Time frame: From Entry Visit until Last Visit (up to 162 months)

  3. Responder Rate in POS (Type I) Frequency Over the Evaluation Period

    A responder is defined as a participant with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

    Time frame: From Entry Visit until Last Visit (up to 162 months)

07

Results

Posted Jul 16, 2020

Participant flow

The study started to enroll patients in September 2005 and concluded in May 2019.

Participant flow — Overall Study
MilestoneBrivaracetam
Started853
Completed234
Not completed619
Withdrew: Death19
Withdrew: Adverse event81
Withdrew: Lack of efficacy354
Withdrew: Lost to follow-up17
Withdrew: Subject choice98
Withdrew: Lack of compliance8
Withdrew: Patient cannot record seizures1
Withdrew: Sponsor decision17
Withdrew: Vigabatrin intake1
Withdrew: Suicidal behaviour1
Withdrew: Withdrawal by subject1
Withdrew: Seizure - free4
Withdrew: Administrative reason1
Withdrew: Pregnancy1
Withdrew: Patient's request2
Withdrew: Treating physiciant's choice1
Withdrew: Moved overseas1
Withdrew: Loss of job and economic burden1
Withdrew: Site was closed9
Withdrew: Patient went to prison1

Outcome measures

PrimaryPercentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

Treatment-emergent adverse events (TEAEs) were defined as those events which started on or after the date of first dose of investigational medicinal product (IMP), or events in which severity worsened on or after the date of first dose of study medication. The event does not necessarily have a causal relationship with that treatment or usage.

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)84.4
PrimaryPercentage of Participants Who Withdrew Due to an Adverse Event (AE)

An AE is any untoward medical occurrence in a participant or trial participant that is administered a drug or biologic (medicinal product) or that is using a medical device. The event does not necessarily have a causal relationship with that treatment or usage.

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdrew Due to an Adverse Event (AE)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants Who Withdrew Due to an Adverse Event (AE)11.6
PrimaryPercentage of Participants With at Least One Serious Adverse Event (SAE)

A serious adverse event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization * Is a congenital anomaly or birth defect * Is an infection that requires treatment parenteral antibiotics * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least One Serious Adverse Event (SAE)
Percentage of participantsBrivaracetam (SS)
Percentage of Participants With at Least One Serious Adverse Event (SAE)29.4
SecondaryPartial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period

The 28 day adjusted seizure frequency was calculated by dividing the number of partial seizures by the number of days for which the diary was completed, and multiplying the resulting value by 28. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Median · Seizures per 28 days
Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days During the Evaluation Period
Seizures per 28 daysBrivaracetam (POS Efficacy)
Baseline8.4 (5.0 to 16.1)
On Treatment4.9 (2.1 to 10.8)
SecondaryPercent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period

The percent change from the previous study baselines, in Partial Onset Seizure (POS) (Type I) frequency per 28 days is defined as: (the value at the previous study baselines) minus (the value at each time-points during the evaluation period) divided by the value at the previous study baselines. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Median · Percent change
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period
Percent changeBrivaracetam (POS Efficacy)
Percent Change in Partial Onset Seizure (POS) (Type I) Frequency Per 28 Days From Baseline of the Previous Study to the Evaluation Period43.1 (9.9 to 71.5)
SecondaryResponder Rate in POS (Type I) Frequency Over the Evaluation Period

A responder is defined as a participant with a ≥ 50% reduction in seizure frequency from the Baseline Period of the previous study. Baseline values for seizure frequency were calculated based on the seizure diary data collected during the baseline period of the previous double-blind studies: N01114 \[NCT00175929\], N01252 \[NCT00490035\] and N01254 \[NCT00504881\].

Time frame:
From Entry Visit until Last Visit (up to 162 months)
Reported as:
Number · Percentage of participants
Responder Rate in POS (Type I) Frequency Over the Evaluation Period
Percentage of participantsBrivaracetam (POS Efficacy)
Responder Rate in POS (Type I) Frequency Over the Evaluation Period43.6

Adverse events

Collected over From Entry Visit until Last Visit (up to 162 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam (SS)19/853 (2.2%)248/853 (29.1%)569/853 (66.7%)
Most frequent serious events
Showing 10 of 286
Most frequent serious events
EventBrivaracetam (SS)
ConvulsionNervous system disorders36/853
EpilepsyNervous system disorders11/853
Head injuryInjury, poisoning and procedural complications10/853
Status epilepticusNervous system disorders10/853
PneumoniaInfections and infestations9/853
MyoclonusNervous system disorders9/853
Grand mal convulsionNervous system disorders8/853
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders7/853
Suicidal ideationPsychiatric disorders7/853
SepsisInfections and infestations6/853
Most frequent other events
Showing 10 of 21
Most frequent other events
EventBrivaracetam (SS)
HeadacheNervous system disorders186/853
NasopharyngitisInfections and infestations157/853
DizzinessNervous system disorders123/853
ConvulsionNervous system disorders112/853
FatigueGeneral disorders84/853
DiarrhoeaGastrointestinal disorders78/853
Back painMusculoskeletal and connective tissue disorders77/853
Urinary tract infectionInfections and infestations75/853
SomnolenceNeoplasms benign, malignant and unspecified (incl cysts and polyps)73/853
InsomniaPsychiatric disorders71/853

Baseline characteristics

Baseline Characteristics refer to the Safety Set which consisted of all participants who took at least 1 dose of study medication.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years14
Between 18 and 65 years827
>=65 years12
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean37.5 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female418
Male435
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brivaracetam
White721
Black2
Asian123
Other7
08

Study locations

153 sites
  • 935
    San Francisco, California 94115, United States
  • 933
    Gainesville, Florida 32610, United States
  • 931
    Charlottesville, Virginia 22908, United States
  • 509
    Graz, Austria
  • 507
    Innsbruck, Austria
  • 510
    Linz, Austria
  • 508
    Wien, Austria
  • 501
    Edegem, Antwerpen, Belgium
  • 515
    Montignies sur Sambre, Chaleroi, Belgium
  • 506
    Brugge, Belgium
  • 513
    Gent, Belgium
  • 974
    La Louvière, Belgium
  • 505
    Leuven, Belgium
  • 951
    Vancouver, British Columbia, Canada
  • 950
    Montreal, Quebec, Canada
  • 952
    Quebec, Canada
  • 545
    Beroun, Czechia
  • 543
    Brno, Czechia
  • 544
    Brno, Czechia
  • 546
    Ceske Budejovice, Czechia
  • 519
    Ostrava Trebovice, Czechia
  • 541
    Praha 1, Czechia
  • 517
    Praha 2, Czechia
  • 542
    Praha 5, Czechia
  • 518
    Zlin, Czechia
  • 900
    Helsinki, Finland
  • 581
    Kuopio, Finland
  • 526
    Oulu, Finland
  • 582
    Oulu, Finland
  • 527
    Seinajoki, Finland
  • 583
    Tampere, Finland
  • 811
    Tampere, Finland
  • 633
    Lyon, Bron, France
  • 632
    Angers Cedex 1, France
  • 628
    Bethune, France
  • 630
    Dijon, France
  • 624
    Lille, France
  • 625
    Marseille, France
  • 623
    Montpellier Cedex 5, France
  • 635
    Nancy, France
  • 626
    Paris, France
  • 920
    Paris, France
  • 622
    Rennes, France
  • 528
    Roanne, France
  • 823
    St Pierre Cedex, France
  • 627
    Strasbourg, France
  • 634
    Toulouse Cedex 04, France
  • 532
    Bad Berka, Germany
  • 705
    Berlin, Germany
  • 708
    Berlin, Germany
  • 536
    Bernau, Germany
  • 707
    Bielefeld, Germany
  • 701
    Bonn, Germany
  • 709
    Erlangen, Germany
  • 703
    Frankfurt, Germany
  • 711
    Freiburg, Germany
  • 537
    Göttingen, Germany
  • 535
    Jena, Germany
  • 710
    Kehl, Germany
  • 531
    Liegau-Augustusbad, Germany
  • 533
    Mainz, Germany
  • 560
    Munchen, Germany
  • 706
    Munchen, Germany
  • 704
    Ulm, Germany
  • 649
    Hong Kong, Hong Kong
  • 650
    Shatin, Hong Kong
  • 547
    Budapest, Hungary
  • 538
    Debrecen, Hungary
  • 539
    Pecs, Hungary
  • 970
    Tel Aviv, Israel
  • 830
    Bologna, Italy
  • 553
    Foggia, Italy
  • 831
    Messina, Italy
  • 563
    Milano, Italy
  • 832
    Milano, Italy
  • 833
    Napoli, Italy
  • 554
    Pavia, Italy
  • 550
    Perugia, Italy
  • 552
    Roma, Italy
  • 555
    Roma, Italy
  • 559
    Roma, Italy
  • 973
    Siena, Italy
  • 655
    Gwangju, Korea, Republic of
  • 652
    Seoul, Korea, Republic of
  • 653
    Seoul, Korea, Republic of
  • 654
    Seoul, Korea, Republic of
  • 656
    Seoul, Korea, Republic of
  • 566
    Breda, Netherlands
  • 567
    Den Haag, Netherlands
  • 821
    Heemstede, Netherlands
  • 822
    Heeze, Netherlands
  • 571
    Fredrikstad, Norway
  • 568
    Oslo, Norway
  • 569
    Sandvika, Norway
  • 570
    Trondheim, Norway
  • 575
    Bialystok, Poland
  • 741
    Gdansk, Poland
  • 978
    Grodzisk Mazowiecki, Poland
  • 748
    Katowice, Poland
  • 976
    Katowice, Poland

Showing the first 100 of 153 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moseley BD, Dimova S, Elmoufti S, Laloyaux C, Asadi-Pooya AA. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis. Epilepsy Res. 2021 Oct;176:106694. doi: 10.1016/j.eplepsyres.2021.106694. Epub 2021 Jun 24. PubMed 34218211 ↗
  • Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. PubMed 33461041 ↗
  • Markham A. Brivaracetam: First Global Approval. Drugs. 2016 Mar;76(4):517-22. doi: 10.1007/s40265-016-0555-6. PubMed 26899665 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2005 to primary completion in May 2019, 164 months.

Results were first posted in Jul 2020, 1 year 2 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 164 months is above that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
StartActual
Sep 2005
Primary completionActual
May 2019
CompletionActual
May 2019
Results first posted
Jul 16, 2020
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00175916
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Sep 2005
Primary completion
May 2019
Completion
May 2019
Results posted
Jul 16, 2020
Last update
Aug 17, 2021

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion